

Pfizer Inc Stock Code PFE.NYS

Outlook

The price uptrend since early May 2018 has ended at \$45.81 on the 9th of Oct. There was a bearish divergence warning from MACD when price made that high. Price has also dropped below a trend line that held up price for most part of the May-Oct rally. On Friday, price's inability to surmount this same trend line is another hint of a possible decline on the cards. MACD has also turned lower, supporting a bearish view. The next strong support level for price lies at \$39.47, which was also a previous high price back in Feb 2018.

Strategy

\$43.20 Short Sell
 \$39.50 Price Target
 \$45.20 Risk Management Stop
 3 weeks Trade Duration

CFD Info				
Code	Security Name	Margin Rate	Long Financing	Short Financing
PFE.NYS	Pfizer Inc	10%	4.50%	3%

Initial Margin: 10%
 Margin Lot Size: 1
 Short Sell (Y/N): Y



American Express Bank Stock Code AXP.NYS

Outlook


Price on Friday closed below a recent low. This could be the start of more downsides to come. MACD has also failed to move into positive zone when there was a price rally. MACD has turned lower in the past few days. Coupled with a bearish divergence when price hit its highest at \$111.77 on the 19th of Sep 2018, there are signs that price has peaked and a corrective down side move is likely. The next strong support comes in at \$95.65. This is a previous low support as well as a gap support.

Strategy

\$101.50 Short Sell
 \$96.00 Price Target
 \$105.50 Risk Management Stop
 3 weeks Trade Duration

CFD Info				
Code	Security Name	Margin Rate	Long Financing	Short Financing
AXP.NYS	American Express Company	10%	4.50%	3%

Initial Margin: 10%
 Margin Lot Size: 1
 Short Sell (Y/N): Y



Disclaimers

This information is prepared by personnel in UOB Kay Hian's Alternative Products Team and is not the product of UOB Kay Hian's Research Department. It is not a research report and is not intended as such, although a UOB Kay Hian Research report may be referenced as a link or as an attachment hereto.

Opinions expressed herein may differ from the opinions expressed by other areas of UOB Kay Hian, including research. This commentary is provided for information only. Neither the information nor any views expressed constitutes a solicitation for the purchase or sale of any securities or other financial instruments. It is not a personal recommendation, offer or solicitation to buy or sell.